Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity.  In this podcast, my friend Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN presents on the benefits as well as the challenges of new models of clinical trials in lung cancer that move away from "all comers" to smaller, more limited populations defined by molecular markers.   Following his presentation, we continued our panel discussion, covering how much the transition into molecular oncology has disrupted how we do clinical research, as well as how our growing experience with molecular testing is leading us to question some of our previously held beliefs.

Below are the audio and video versions of this podcast, along with the transcript and figures for it.

[powerpress]

Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Audio Podcast

Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Transcript

Molecular Markers SM Pt 5 Spigel on Markers in Clinical Trials Figs

The last part of the program will be Dr. Glen Goss speaking on efforts to integrate collection of molecular markers across a network or health care system -- look for that soon.

And thanks again to LUNGevity Foundation for partnering with us to produce this program and the subsequent podcasts produced from it.

Finally, I'll just say that I do intend to write some of my own new posts soon.  For now, I'm still working to catch up on several other commitments that were put on ice so that I could get through my recent grueling medical board recertification.  I'll be digging myself out soon.